Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1136)	6/23/2005 1:01:30 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GNLB was up more than 24% on volume above 18M after the FDA confirmed that Prestara qualifies for "orphan drug" designation for the prevention of osteoporosis in LE patients on steroids. Last October the PIII didn't show statistical significant results in women with LE, but on further analysis of the data showed that patients on Prestara had a mean increase in BMD at the lumbar spine compared to a decrease patients on placebo, albeit the results were still considered not "statistically significant".<g> The stock closed above its June 1 H of 0.62 but it now needs to close today's upgap.<g> bigcharts.marketwatch.com Bernard